GlassScriptPhysician profile
Kaitlyn Ann Benjamin
NPI 1144729518
$7,879.54
in general payments reported to CMS, 2019-2025
29 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $705 · 2022: $506 · 2023: $2,988 · 2024: $2,030 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,425 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,424.56 |
| Education | $243.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,033.50 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $766.72 | 2021-2025 | |
| Incyte Corporation | $692.34 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $651.28 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $555.70 | 2023-2025 | |
| Amgen INC. | $490.80 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $439.30 | 2023-2024 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $429.43 | 2023-2025 | Sotyktu, Sprycel |
| Lilly USA, LLC | $362.76 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $289.47 | 2022-2023 | Dupixent, Libtayo |
| Pfizer INC. | $280.24 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $276.39 | 2023-2025 | |
| Galderma Laboratories, L.P. | $215.50 | 2021-2025 | Nemluvio |
| Kerecis Limited | $211.78 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Arcutis Biotherapeutics, INC. | $201.23 | 2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.50 | 2023-2024 | Spevigo |
| Convatec INC. | $165.77 | 2023-2025 | |
| Dermavant Sciences, INC. | $132.01 | 2024 | Vtama |
| Journey Medical Corporation | $104.22 | 2022 | |
| Janssen Scientific Affairs, LLC | $88.57 | 2021 | |
| Mayne Pharma Commercial LLC | $86.12 | 2023-2025 | |
| Biofrontera INC. | $66.12 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Triad Life Sciences INC. | $25.02 | 2022 | |
| Almirall LLC | $24.53 | 2025 | Seysara |
| Helsinn Therapeutics (U.S.), INC. | $24.01 | 2023 | Valchlor |
| Verrica Pharmaceuticals INC. | $23.20 | 2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $22.62 | 2023 | Nuzyra |
| Leo Pharma INC. | $19.66 | 2024 | Adbry |
| Tactile Systems Technology INC | $15.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.